Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 1;127(13):2196-2203.
doi: 10.1002/cncr.33489. Epub 2021 Mar 18.

Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-A National Cancer Database analysis

Nina Tamirisa  1 , Heather Lin  2 , Yu Shen  2 , Simona F Shaitelman  3 , Meghan S Karuturi  4 , Sharon H Giordano  4   5 , Gildy V Babiera  6 , Isabelle Bedrosian  1
Affiliations

Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-A National Cancer Database analysis

Nina Tamirisa et al. Cancer. .

Erratum in

Abstract

Background: Data are lacking about the benefit of adjuvant endocrine therapy (ET) in older patients with multiple comorbidities. The authors sought to determine the effect of ET on the survival of older patients who had multiple comorbidities and estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative, pathologic node-negative (pN0) breast cancer.

Methods: Women aged ≥70 years in the National Cancer Database (2010-2014) with Charlson/Deyo comorbidity scores of 2 or 3 who had pathologic tumor (pT1)-pT3/pN0, ER-positive/HER2-negative breast cancer were divided into 2 cohorts: adjuvant ET and no ET. Propensity scores were used to match patients based on age, comorbidity score, facility type, pT classification, chemotherapy, surgery, and radiation therapy. A Cox proportional hazards model was used to estimate the effect of ET on overall survival (OS).

Results: In the nonmatched cohort (n = 3716), 72.8% of patients received ET (n = 2705), and 27.2% did not (n = 1011). The patients who received ET were younger (mean age, 76 vs 79 years; P < .001) and had higher rates of breast conservation compared with those who did not receive ET (lumpectomy plus radiation: 43.4% vs 23.8%, respectively; P < .001). In the matched cohort (n = 1972), the median OS was higher in the ET group (79.2 vs 67.7 months; P < .0001). In the adjusted analysis, ET was associated with improved survival (hazard ratio, 0.70; 95% CI, 0.59-0.83).

Conclusions: In older patients who have pN0, ER-positive/HER2-negative breast cancer with comorbidities, adjuvant ET was associated with improved OS, which may have been overestimated given the confounders inherent in observational studies. To optimize outcomes in these patients, current standard recommendations should be considered stage-for-stage based on life expectancy and the level of tolerance to treatment.

Keywords: adjuvant; breast cancer; endocrine therapy; older.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan–Meier curves for overall survival. National Cancer Data Base 2010–2014, Patients ≥70 with cT1–3/pN0, Estrogen Receptor Positive/Human epidermal growth factor receptor 2 Negative invasive breast cancer treated with breast and axillary surgery a. nonmatched (N= 3,716)and b. matched (N=1,972) cohorts, comparing endocrine therapy to no endocrine therapy
Figure 1.
Figure 1.
Kaplan–Meier curves for overall survival. National Cancer Data Base 2010–2014, Patients ≥70 with cT1–3/pN0, Estrogen Receptor Positive/Human epidermal growth factor receptor 2 Negative invasive breast cancer treated with breast and axillary surgery a. nonmatched (N= 3,716)and b. matched (N=1,972) cohorts, comparing endocrine therapy to no endocrine therapy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Derks MGM, Blok EJ, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017; 18(9):1211–1220. - PubMed
    1. Muss HB, Tu D, Ingle JN, et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 2008; 26(12):1956–64. - PubMed
    1. Crivellari D, Sun Z, Coates AS, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1–98 trial. J Clin Oncol 2008; 26(12):1972–9. - PubMed
    1. Chirgwin JH, Giobbie-Hurder A, Coates AS, et al. Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1–98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. J Clin Oncol 2016; 34(21):2452–9. - PMC - PubMed
    1. Biganzoli L, Wildiers H, Oakman C, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012; 13(4):e148–60. - PubMed

Publication types